The TSC2 gene, which encodes the tumor suppressor protein tuberin, is a critical member of the tuberous sclerosis complex (TSC) gene family that operates in conjunction with TSC1 (hamartin) to form a heterodimeric complex essential for the precise regulation of cellular growth and proliferation. This TSC1-TSC2 complex functions as a central negative regulator of the mechanistic target of rapamycin (mTOR) signaling pathway, a master controller that integrates growth factor, energy, and nutrient signals to govern cell metabolism, protein synthesis, and overall cellular homeostasis. By inhibiting mTOR activity, tuberin ensures that cell division and growth are appropriately modulated in response to environmental cues; however, loss-of-function mutations in TSC2 disrupt this regulatory mechanism, leading to constitutive mTOR activation that drives abnormal cell proliferation. This dysregulation is the primary driver of tuberous sclerosis complex (TSC), an autosomal dominant genetic disorder characterized by the development of benign hamartomatous tumors in multiple organs, including the brain, kidneys, and skin, often accompanied by clinical manifestations such as epilepsy, intellectual disability, and cutaneous lesions. Furthermore, the disruption of TSC2-mediated mTOR suppression significantly elevates the risk of malignant transformation, particularly renal cell carcinoma, while aberrant overexpression of TSC2 can conversely impair normal cellular growth and repair processes by excessively suppressing mTOR. Consequently, understanding the molecular mechanisms of TSC2 is pivotal for the development of therapeutic strategies, including the use of mTOR inhibitors such as rapamycin analogs, to manage TSC and related malignancies.
Subcellular localization of TSC2 (and its protein):
Gene Ontology (GO) terms for TSC2:
| Interacting Gene | Interaction | Source/Score |
| Name |
|---|
| 4151 PI3K-Akt signaling pathway [PATH:hsa04151] |
| 4152 AMPK signaling pathway [PATH:hsa04152] |
| 4150 mTOR signaling pathway [PATH:hsa04150] |
| 4115 p53 signaling pathway [PATH:hsa04115] |
| 4910 Insulin signaling pathway [PATH:hsa04910] |
| 4919 Thyroid hormone signaling pathway [PATH:hsa04919] |
| 5231 Choline metabolism in cancer [PATH:hsa05231] |
| Name |
|---|
| Adaptive Immune System |
| AKT phosphorylates targets in the cytosol |
| Constitutive Signaling by AKT1 E17K in Cancer |
| DAP12 interactions |
| DAP12 signaling |
| Disease |
| Diseases of signal transduction |
| Downstream signal transduction |
| Downstream signaling events of B Cell Receptor (BCR) |
| Downstream signaling of activated FGFR1 |
| Downstream signaling of activated FGFR2 |
| Downstream signaling of activated FGFR3 |
| Downstream signaling of activated FGFR4 |
| Energy dependent regulation of mTOR by LKB1-AMPK |
| Fc epsilon receptor (FCERI) signaling |
| GAB1 signalosome |
| Gene Expression |
| Generic Transcription Pathway |
| IGF1R signaling cascade |
| Inhibition of TSC complex formation by PKB |
| Innate Immune System |
| Insulin receptor signalling cascade |
| IRS-mediated signalling |
| IRS-related events |
| IRS-related events triggered by IGF1R |
| mTOR signalling |
| NGF signalling via TRKA from the plasma membrane |
| PI-3K cascade:FGFR1 |
| PI-3K cascade:FGFR2 |
| PI-3K cascade:FGFR3 |
| PI-3K cascade:FGFR4 |
| PI3K Cascade |
| PI3K events in ERBB2 signaling |
| PI3K events in ERBB4 signaling |
| PI3K/AKT activation |
| PI3K/AKT Signaling in Cancer |
| PIP3 activates AKT signaling |
| PKB-mediated events |
| Regulation of Rheb GTPase activity by AMPK |
| Role of LAT2/NTAL/LAB on calcium mobilization |
| Signaling by EGFR |
| Signaling by ERBB2 |
| Signaling by ERBB4 |
| Signaling by FGFR |
| Signaling by FGFR1 |
| Signaling by FGFR2 |
| Signaling by FGFR3 |
| Signaling by FGFR4 |
| Signaling by Insulin receptor |
| Signaling by PDGF |
| Signaling by SCF-KIT |
| Signaling by the B Cell Receptor (BCR) |
| Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) |
| Signalling by NGF |
| TP53 Regulates Metabolic Genes |
| Transcriptional Regulation by TP53 |
| Disease | Score | NofPmids | NofSnps | Source |
| Lymphangioleiomyomatosis | 0.576859191 | 35 | 5 | BeFree_CLINVAR_CTD_human_LHGDN_MGD_ORPHANET_UNIPROT |
| Tuberous Sclerosis | 0.493815383 | 277 | 72 | BeFree_CLINVAR_CTD_human_GAD_LHGDN_ORPHANET |
| TUBEROUS SCLEROSIS 2 (disorder) | 0.441357209 | 14 | 71 | BeFree_CLINVAR_CTD_human_MGD_UNIPROT |
| Autistic Disorder | 0.203810118 | 6 | 0 | BeFree_CTD_human_LHGDN_MGD |
| Epilepsy | 0.126710102 | 17 | 0 | BeFree_CTD_human_GAD |
| Squamous cell carcinoma | 0.122995792 | 2 | 0 | BeFree_CTD_human_LHGDN |
| Pancreatic Neoplasm | 0.12272435 | 2 | 0 | CTD_human_LHGDN |
| Kidney Neoplasm | 0.122171535 | 11 | 0 | BeFree_CTD_human |
| Seizures | 0.121900093 | 8 | 0 | BeFree_CTD_human |
| West Syndrome | 0.121628651 | 7 | 0 | BeFree_CTD_human |
No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong
Qilu Normal University · Genelibs Bioinformatics Lab
750 Shunhua Rd, Jinan
2F, Bldg F, University Science Park
Tel: 0531-88819269
Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.
Business Email
E-mail: [email protected]